Status | Study |
RECRUITING |
Study Name: Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Condition: Pancreatic Neuroendocrine Tumor Date: 2022-11-02 Interventions: Cytoreductive surgery is an operation to remove as much tumor tissue as possible. |
Recruiting |
Study Name: Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) Condition: Multiple Endocrine Neoplasia Pancreatic Neuroendocrine Tumors Date: 2017-02-13 Interventions: Other: Genome Sequencing Analy |
Recruiting |
Study Name: Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery Condition: Pancreatic Neuroendocrine Tumor G1 Pancre Date: 2016-09-08 Interventions: Drug: Sapanisertib Given PO Other Names: |
Recruiting |
Study Name: Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria Condition: Pancreatic Neuroendocrine Tumors Date: 2016-07-20 |
Recruiting |
Study Name: Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Condition: Pancreatic Neuroendocrine Tumors Date: 2016-06-16 Interventions: Drug: everolimus Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be prov |
Active, not recruiting |
Study Name: Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Condition: Non Functioning Pancreatic Endocrine Tumor Date: 2016-04-26 Interventions: Biological: Chromogranin A The plasma level of chromogranin A (CgA) was measured in enrolled patients wh |
Recruiting |
Study Name: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Condition: Gastro-entero-pancreatic Neuroendocrine Tumors Date: 2016-04-07 Interventions: Drug: Capecitabine oral low do |
Active, not recruiting |
Study Name: Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Condition: Neuroendocrine Tumors Gastro Entero Pancreatic Neuroendocrine Tumors Date: 2016-04-07 Interventions: Drug: 28 GBq 177Lu-DOTATATE Pa |
Not yet recruiting |
Study Name: Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Who Previously Failed to Sunitinib Condition: Pancreatic Neuroendocrine Tumour Metastatic Date: 2016-03-16 Interventions: Drug: Sunitinib Sunitinib 37.5 mg/day |
Not yet recruiting |
Study Name: Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment Condition: Pancreatic Neuroendocrine Tumors in MEN1 Date: 2016-03-02 Interventions: Drug: Somatostatin-Analog A long-acting somatostatin-analog will be applied. |